Clinical Report: Approaches to Addressing Hypogammaglobulinemia in Pediatric Patients

Overview

This report examines the safety and efficacy of belimumab in pediatric patients with refractory lupus nephritis (LN) and hypogammaglobulinemia. Findings indicate a high incidence of hypogammaglobulinemia among patients and an increased risk of infections associated with belimumab treatment.

Background

Lupus nephritis is a severe manifestation of systemic lupus erythematosus (SLE) and poses significant treatment challenges. The introduction of belimumab has provided a new therapeutic option, but its safety profile in pediatric patients with hypogammaglobulinemia remains underexplored. Understanding the implications of belimumab treatment in this population is crucial for optimizing patient outcomes.

Data Highlights

Key Findings

• Hypogammaglobulinemia was present in 81.5% of patients with LN prior to treatment.
• Belimumab treatment was associated with a higher incidence of infections compared to standard therapy.
• Serum IgG levels were significantly lower in the belimumab group.
• ESR was significantly lower in the belimumab group at weeks 12 and 24.
• C3 levels were significantly higher in the belimumab group at weeks 24 and 52.
• Patients with serum IgG levels below 4 g/L required intravenous immunoglobulin (IVIG) therapy due to infections.

Clinical Implications

Clinicians should be vigilant in monitoring IgG levels in pediatric patients with LN receiving belimumab, as hypogammaglobulinemia can lead to increased infection risk. Aggressive IgG replacement therapy may be necessary for patients with low serum IgG levels to mitigate infection risks.

Conclusion

The findings highlight the need for careful management of hypogammaglobulinemia in pediatric patients with LN undergoing belimumab treatment, emphasizing the importance of monitoring and potential IVIG therapy.

References

1. Clinical Rheumatology, The Advent of Biologic Therapies for Systemic Lupus Erythematosus Management, 2017 -- https://link.springer.com/article/10.1007/s10067-017-3933-x
2. Clinical Rheumatology, Exploring the Role of Belimumab in Connective Tissue Disorders and Vasculitis, 2025 -- https://link.springer.com/article/10.1007/s10067-025-07847-5
3. Clinical Rheumatology, Exploring the Application of Belimumab in Spanish Patients with Systemic Lupus Erythematosus, 2022 -- https://link.springer.com/article/10.1007/s10067-022-06287-9
4. The ASCO Post, Genomics Now Driving Treatment of Waldenström’s Macroglobulinemia, 2015 -- https://ascopost.com/issues/november-25-2015/genomics-now-driving-treatment-of-waldenstroem-s-macroglobulinemia/
5. Lupus Nephritis Guideline Summary 2024 -- https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt4db6d0b451e88caf/lupus-nephritis-guideline-summary-2024.pdf
6. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis - PubMed -- https://pubmed.ncbi.nlm.nih.gov/32937045/?utm_source=openai
7. Clinical Rheumatology — The Advent of Biologic Therapies for Systemic Lupus Erythematosus Management
8. Clinical Rheumatology — Exploring the Role of Belimumab in Connective Tissue Disorders and Vasculitis: A Comprehensive Review Beyond Systemic Lupus Erythematosus
9. Clinical Rheumatology — Exploring the Application of Belimumab in Spanish Patients with Systemic Lupus Erythematosus: A Scoping Review of Patient Characteristics
10. The ASCO Post — Genomics Now Driving Treatment of Waldenström’s Macroglobulinemia
11. https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt4db6d0b451e88caf/lupus-nephritis-guideline-summary-2024.pdf
12. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis - PubMed